Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Spectral AI develops AI-powered medical imaging devices for wound assessment and burn triage, with its DeepView System targeting military, hospital, and wound care center markets. The company is pre-commercialization with minimal revenue ($0.4M TTM estimated), burning cash while pursuing FDA clearances and Department of Defense contracts. Stock trades on regulatory milestone expectations and capital raise needs rather than operational fundamentals.
Spectral AI's business model centers on selling AI-powered wound assessment devices that use multispectral imaging to predict healing outcomes within 1-2 minutes versus traditional 2-3 week observation periods. The company targets a razor-razorblade model where initial device placements (estimated $50-80K per unit) generate recurring revenue from disposable imaging cartridges and software subscriptions. Primary near-term revenue depends on securing DoD procurement contracts for battlefield burn triage and VA hospital deployments, followed by commercial hospital penetration. Pricing power remains unproven given lack of commercial traction and competition from established wound care companies. Competitive advantage hinges on proprietary AI algorithms trained on burn datasets and potential first-mover status in AI-based wound assessment, though clinical validation and reimbursement pathways remain uncertain.
FDA 510(k) clearance announcements for DeepView System indications (burn assessment, diabetic foot ulcers, surgical wounds)
Department of Defense contract awards and procurement milestones for military burn triage applications
Clinical trial data releases demonstrating diagnostic accuracy, sensitivity/specificity metrics, and healing prediction performance
Capital raising announcements (equity offerings, warrant exercises) that signal runway extension but create dilution pressure
Commercial partnership agreements with hospital systems, wound care networks, or medical device distributors
FDA regulatory pathway uncertainty for AI-based diagnostic devices with evolving guidance on algorithm validation, clinical evidence requirements, and post-market surveillance obligations that could delay or prevent commercialization
Reimbursement risk as payers (CMS, private insurers) lack established CPT codes or coverage policies for AI wound assessment, potentially limiting adoption even with FDA clearance
Technological obsolescence risk from rapid AI/machine learning advancement and competition from established medical imaging companies (GE Healthcare, Philips, Siemens) entering wound assessment market with superior resources
Established wound care companies (Smith+Nephew, Mölnlycke, 3M) could integrate AI capabilities into existing product portfolios with stronger hospital relationships and distribution networks
Alternative diagnostic approaches (infrared thermography, laser Doppler imaging, biomarker testing) may prove superior or gain earlier regulatory/reimbursement approval
Low barriers to entry for software-based diagnostic tools once clinical validation pathways are established, risking commoditization of AI wound assessment
Critical liquidity risk with 0.85x current ratio and estimated 6-12 month cash runway requiring imminent capital raise that will significantly dilute existing shareholders at depressed valuation
Negative tangible book value (-$4.9x P/B) and -107% ROA indicate asset base cannot support operations, making company entirely dependent on external financing
Warrant overhang and potential down-round financing risk given 22% one-year stock decline, creating death spiral dynamics if equity raises occur below previous financing rounds
moderate - Hospital capital equipment budgets exhibit cyclical sensitivity as healthcare systems defer discretionary technology purchases during economic downturns. However, government defense spending (DoD contracts) provides countercyclical stability. Commercial adoption depends on hospital financial health and elective procedure volumes, which correlate with consumer spending and employment levels. Pre-revenue status means company is more sensitive to capital markets conditions (ability to raise funding) than end-market demand currently.
High sensitivity through multiple channels: (1) Higher rates compress valuation multiples for unprofitable growth companies, particularly impacting microcap biotech/medtech stocks trading on future earnings potential. (2) Rising rates increase cost of capital for cash-burning operations, making dilutive equity raises more expensive and reducing investor appetite for speculative healthcare names. (3) Hospital customers face higher financing costs for capital equipment purchases, potentially delaying adoption. (4) Competition for investor capital intensifies as risk-free rates rise, reducing allocation to high-risk pre-commercial medical device plays.
Moderate - Company's survival depends on access to equity capital markets rather than debt financing given negative cash flow and minimal assets for collateral. Credit market tightening indirectly impacts stock through reduced venture/growth equity availability and investor risk appetite. Hospital customers' creditworthiness affects receivables collection post-commercialization, though currently immaterial given minimal revenue base.
growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from pre-commercial medical device plays with binary regulatory outcomes. Typical shareholders include retail momentum traders, microcap biotech specialists, and early-stage healthcare venture investors willing to accept 70-90% downside risk for potential 5-10x upside if commercialization succeeds. Not suitable for value or income investors given negative earnings, no dividends, and uncertain path to profitability. Institutional ownership likely minimal given sub-$50M market cap and liquidity constraints.
high - Microcap pre-revenue medical device stocks exhibit extreme volatility (estimated beta 2.0-3.0x) driven by binary regulatory events, capital raise announcements, and low float/liquidity. Stock demonstrates this pattern with -28% six-month return despite +5.6% three-month bounce, reflecting episodic news-driven swings. Daily trading volumes likely thin, creating wide bid-ask spreads and susceptibility to manipulation. Volatility will remain elevated until commercial revenue provides fundamental valuation anchor.
